These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 28667074)

  • 1. LSD1 Inhibitor T-3775440 Inhibits SCLC Cell Proliferation by Disrupting LSD1 Interactions with SNAG Domain Proteins INSM1 and GFI1B.
    Takagi S; Ishikawa Y; Mizutani A; Iwasaki S; Matsumoto S; Kamada Y; Nomura T; Nakamura K
    Cancer Res; 2017 Sep; 77(17):4652-4662. PubMed ID: 28667074
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Novel LSD1 Inhibitor T-3775440 Disrupts GFI1B-Containing Complex Leading to Transdifferentiation and Impaired Growth of AML Cells.
    Ishikawa Y; Gamo K; Yabuki M; Takagi S; Toyoshima K; Nakayama K; Nakayama A; Morimoto M; Miyashita H; Dairiki R; Hikichi Y; Tomita N; Tomita D; Imamura S; Iwatani M; Kamada Y; Matsumoto S; Hara R; Nomura T; Tsuchida K; Nakamura K
    Mol Cancer Ther; 2017 Feb; 16(2):273-284. PubMed ID: 27903753
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A DNA Hypomethylation Signature Predicts Antitumor Activity of LSD1 Inhibitors in SCLC.
    Mohammad HP; Smitheman KN; Kamat CD; Soong D; Federowicz KE; Van Aller GS; Schneck JL; Carson JD; Liu Y; Butticello M; Bonnette WG; Gorman SA; Degenhardt Y; Bai Y; McCabe MT; Pappalardi MB; Kasparec J; Tian X; McNulty KC; Rouse M; McDevitt P; Ho T; Crouthamel M; Hart TK; Concha NO; McHugh CF; Miller WH; Dhanak D; Tummino PJ; Carpenter CL; Johnson NW; Hann CL; Kruger RG
    Cancer Cell; 2015 Jul; 28(1):57-69. PubMed ID: 26175415
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting NOTCH activation in small cell lung cancer through LSD1 inhibition.
    Augert A; Eastwood E; Ibrahim AH; Wu N; Grunblatt E; Basom R; Liggitt D; Eaton KD; Martins R; Poirier JT; Rudin CM; Milletti F; Cheng WY; Mack F; MacPherson D
    Sci Signal; 2019 Feb; 12(567):. PubMed ID: 30723171
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Jumonji histone demethylases are therapeutic targets in small cell lung cancer.
    Nguyen A; Nuñez CG; Tran TA; Girard L; Peyton M; Catalan R; Guerena C; Avila K; Drapkin BJ; Chandra R; Minna JD; Martinez ED
    Oncogene; 2024 Sep; 43(38):2885-2899. PubMed ID: 39154123
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Insulinoma-Associated Protein 1 Is a Crucial Regulator of Neuroendocrine Differentiation in Lung Cancer.
    Fujino K; Motooka Y; Hassan WA; Ali Abdalla MO; Sato Y; Kudoh S; Hasegawa K; Niimori-Kita K; Kobayashi H; Kubota I; Wakimoto J; Suzuki M; Ito T
    Am J Pathol; 2015 Dec; 185(12):3164-77. PubMed ID: 26482608
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regulation of neuroendocrine plasticity by the RNA-binding protein ZFP36L1.
    Chen HY; Durmaz YT; Li Y; Sabet AH; Vajdi A; Denize T; Walton E; Laimon YN; Doench JG; Mahadevan NR; Losman JA; Barbie DA; Tolstorukov MY; Rudin CM; Sen T; Signoretti S; Oser MG
    Nat Commun; 2022 Aug; 13(1):4998. PubMed ID: 36008402
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Growth Factor Independence 1B-Mediated Transcriptional Repression and Lineage Allocation Require Lysine-Specific Demethylase 1-Dependent Recruitment of the BHC Complex.
    McClellan D; Casey MJ; Bareyan D; Lucente H; Ours C; Velinder M; Singer J; Lone MD; Sun W; Coria Y; Mason CC; Engel ME
    Mol Cell Biol; 2019 Jul; 39(13):. PubMed ID: 30988160
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Trastuzumab emtansine suppresses the growth of HER2-positive small-cell lung cancer in preclinical models.
    Morimura O; Minami T; Kijima T; Koyama S; Otsuka T; Kinehara Y; Osa A; Higashiguchi M; Miyake K; Nagatomo I; Hirata H; Iwahori K; Takimoto T; Takeda Y; Kida H; Kumanogoh A
    Biochem Biophys Res Commun; 2017 Jul; 488(4):596-602. PubMed ID: 28526406
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Kdm1a promotes SCLC progression by transcriptionally silencing the tumor suppressor Rest.
    Jin Y; Ma D; Gramyk T; Guo C; Fang R; Ji H; Shi YG
    Biochem Biophys Res Commun; 2019 Jul; 515(1):214-221. PubMed ID: 31146914
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sonic hedgehog signaling pathway promotes INSM1 transcription factor in neuroendocrine lung cancer.
    Chen C; Breslin MB; Lan MS
    Cell Signal; 2018 Jun; 46():83-91. PubMed ID: 29501727
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting epithelial-to-mesenchymal transition with Met inhibitors reverts chemoresistance in small cell lung cancer.
    Cañadas I; Rojo F; Taus Á; Arpí O; Arumí-Uría M; Pijuan L; Menéndez S; Zazo S; Dómine M; Salido M; Mojal S; García de Herreros A; Rovira A; Albanell J; Arriola E
    Clin Cancer Res; 2014 Feb; 20(4):938-50. PubMed ID: 24284055
    [TBL] [Abstract][Full Text] [Related]  

  • 13. T-448, a specific inhibitor of LSD1 enzyme activity, improves learning function without causing thrombocytopenia in mice.
    Matsuda S; Baba R; Oki H; Morimoto S; Toyofuku M; Igaki S; Kamada Y; Iwasaki S; Matsumiya K; Hibino R; Kamada H; Hirakawa T; Iwatani M; Tsuchida K; Hara R; Ito M; Kimura H
    Neuropsychopharmacology; 2019 Jul; 44(8):1505-1512. PubMed ID: 30580376
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Altering the Course of Small Cell Lung Cancer: Targeting Cancer Stem Cells via LSD1 Inhibition.
    Stewart CA; Byers LA
    Cancer Cell; 2015 Jul; 28(1):4-6. PubMed ID: 26175409
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intrinsic and acquired drug resistance to LSD1 inhibitors in small cell lung cancer occurs through a TEAD4-driven transcriptional state.
    Yan W; Chung CY; Xie T; Ozeck M; Nichols TC; Frey J; Udyavar AR; Sharma S; Paul TA
    Mol Oncol; 2022 Mar; 16(6):1309-1328. PubMed ID: 34669238
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CRISPR-suppressor scanning reveals a nonenzymatic role of LSD1 in AML.
    Vinyard ME; Su C; Siegenfeld AP; Waterbury AL; Freedy AM; Gosavi PM; Park Y; Kwan EE; Senzer BD; Doench JG; Bauer DE; Pinello L; Liau BB
    Nat Chem Biol; 2019 May; 15(5):529-539. PubMed ID: 30992567
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting Lysine-Specific Demethylase 1 Rescues Major Histocompatibility Complex Class I Antigen Presentation and Overcomes Programmed Death-Ligand 1 Blockade Resistance in SCLC.
    Nguyen EM; Taniguchi H; Chan JM; Zhan YA; Chen X; Qiu J; de Stanchina E; Allaj V; Shah NS; Uddin F; Manoj P; Liu M; Cai SF; Levine R; Quintanal-Villalonga Á; Sen T; Chow A; Rudin CM
    J Thorac Oncol; 2022 Aug; 17(8):1014-1031. PubMed ID: 35691495
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential transcriptional regulation of meis1 by Gfi1b and its co-factors LSD1 and CoREST.
    Chowdhury AH; Ramroop JR; Upadhyay G; Sengupta A; Andrzejczyk A; Saleque S
    PLoS One; 2013; 8(1):e53666. PubMed ID: 23308270
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Triple marker composed of p16, CD56, and TTF1 shows higher sensitivity than INSM1 for diagnosis of pulmonary small cell carcinoma: proposal for a rational immunohistochemical algorithm for diagnosis of small cell carcinoma in small biopsy and cytology specimens.
    Švajdler M; Mezencev R; Šašková B; Ondič O; Mukenšnábl P; Michal M
    Hum Pathol; 2019 Mar; 85():58-64. PubMed ID: 30385371
    [TBL] [Abstract][Full Text] [Related]  

  • 20. LSD1/KDM1A inhibitors in clinical trials: advances and prospects.
    Fang Y; Liao G; Yu B
    J Hematol Oncol; 2019 Dec; 12(1):129. PubMed ID: 31801559
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.